| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
On CNBC's “Halftime Report Final Trades,” Stephen Weiss of Short Hills Capital Partners named ProShares Short QQQ (NYSE:PSQ) as his final trade.
Jenny Van Leeuwen Harrington of Gilman Hill Asset Management said Organon & Co. (NYSE:OGN) is back to 6% dividend yield.
On Sept. 18, Organon agreed to acquire Roivant Sciences Ltd's (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused on developing and commercializing therapeutics in immunodermatology. Dermavant's novel product, Vtama (tapinarof) cream, 1%, for the topical treatment of mild, moderate, and severe plaque psoriasis in adults, was approved by the FDA in May 2022. Vtama cream is a once-daily, steroid-free, topical therapy applied to affected areas.
Don't forget to check out our premarket coverage here
Joseph M. Terranova of Virtus Investment Partners picked Howmet Aerospace Inc. (NYSE:HWM), an industrial name.
On July 30, Howmet Aerospace reported better-than-expected second-quarter FY24 financial results. The Board of Directors declared a dividend of 8 cents per share, payable on Aug. 26 to shareholders of record as of Aug. 9. Howmet Aerospace increased its revenue outlook to $7.40 billion-$7.48 billion (from $7.225 billion-$7.375 billion) versus the consensus of $7.33 billion and adjusted EPS to $2.53-$2.57 (from $2.31-$2.39) vs. the consensus of $2.39.
Price Action:
Check This Out:
Image Created Using Midjourney
